Syros Pharmaceuticals Stock Forecast, Price & News

-0.12 (-2.36 %)
(As of 09/20/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume50,639 shs
Average Volume931,620 shs
Market Capitalization$307.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals logo

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.11 out of 5 stars

Medical Sector

448th out of 1,352 stocks

Pharmaceutical Preparations Industry

218th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

Is Syros Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Syros Pharmaceuticals?

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Syros Pharmaceuticals

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Thursday, August, 5th. The company reported ($0.36) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.36). The firm had revenue of $5.16 million for the quarter, compared to the consensus estimate of $4.58 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 82.58% and a negative net margin of 442.40%.
View Syros Pharmaceuticals' earnings history

How has Syros Pharmaceuticals' stock price been impacted by Coronavirus?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SYRS stock has decreased by 3.7% and is now trading at $4.96.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SYRS?

6 brokerages have issued 12-month price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $13.00 to $20.00. On average, they expect Syros Pharmaceuticals' stock price to reach $16.20 in the next twelve months. This suggests a possible upside of 226.6% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Nancy A. Simonian, President, Chief Executive Officer & Director
  • Gerald E. Quirk, Chief Operating Officer
  • Eric R. Olson, Chief Scientific Officer
  • David A. Roth, Chief Medical Officer
  • Kristin Stephen, Chief Development Officer

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.61%), BlackRock Inc. (7.21%), Vanguard Group Inc. (4.48%), Omega Fund Management LLC (3.67%), Altium Capital Management LP (1.74%) and State Street Corp (1.61%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young and Srinivas Akkaraju.
View institutional ownership trends for Syros Pharmaceuticals

Which major investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Redmile Group LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, PDT Partners LLC, Russell Investments Group Ltd., State of Wisconsin Investment Board, and Deutsche Bank AG.
View insider buying and selling activity for Syros Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Syros Pharmaceuticals stock?

SYRS stock was bought by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Omega Fund Management LLC, Millennium Management LLC, Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Cubist Systematic Strategies LLC, and State Street Corp. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, and Mark J Alles.
View insider buying and selling activity for Syros Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $4.96.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals has a market capitalization of $307.18 million and generates $15.09 million in revenue each year. The company earns $-84,040,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 103 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is

Where are Syros Pharmaceuticals' headquarters?

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 744-1340 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.